PRCT Stock Price, PROCEPT BioRobotics Quote, Chart

Market Summary

USD52.48-1.27

Market Closed

-2.36%

PRCT Alerts

1 major insider sales recently.

PRCT Stock Price

View Fullscreen

PRCT RSI Chart

PRCT Valuation

Market Cap

2.7B

Price/Earnings (Trailing)

-25.26

Price/Sales (Trailing)

19.64

Price/Free Cashflow

-20.08

PRCT Price/Sales (Trailing)

PRCT Profitability

Operating Margin

52.17%

Return on Equity

-37.72%

Return on Assets

-26.17%

Free Cashflow Yield

-4.98%

PRCT Fundamentals

PRCT Revenue

Revenue (TTM)

136.2M

Rev. Growth (Yr)

83.29%

Rev. Growth (Qtr)

24.16%

PRCT Earnings

Earnings (TTM)

-105.9M

Earnings Growth (Yr)

2.37%

Earnings Growth (Qtr)

-11.71%

Breaking Down PRCT Revenue

Last 7 days

3.4%

Last 30 days

12.8%

Last 90 days

18.6%

Trailing 12 Months

51.6%

How does PRCT drawdown profile look like?

PRCT Financial Health

Current Ratio

7.63

Debt/Equity

0.18

Debt/Cashflow

-2.1

PRCT Investor Care

Shares Dilution (1Y)

12.92%

Diluted EPS (TTM)

-2.24

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	85.2M	101.6M	116.4M	136.2M
2022	41.5M	49.7M	61.4M	75.0M
2021	14.4M	21.1M	27.8M	34.5M
2020	0	0	0	7.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of PROCEPT BioRobotics Corporation

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 18, 2024	wood larry l	acquired	-	-	3,054	-
Mar 18, 2024	waters kevin	sold	-50,001	48.83	-1,024	evp, cfo
Mar 18, 2024	nouri alaleh	sold	-21,534	48.83	-441	evp, clo, corp. sec.
Mar 18, 2024	zadno reza	sold	-263,243	48.83	-5,391	president, ceo
Mar 18, 2024	shiblaq hisham	sold	-11,914	48.83	-244	evp, chief comm. officer
Mar 15, 2024	waters kevin	acquired	487,383	4.53321	107,514	evp, cfo
Mar 06, 2024	shiblaq hisham	acquired	-	-	26,449	evp, chief comm. officer
Mar 06, 2024	zadno reza	acquired	-	-	54,933	president, ceo
Mar 06, 2024	zadno reza	acquired	-	-	48,575	president, ceo
Mar 06, 2024	waters kevin	acquired	-	-	13,275	evp, cfo

Which funds bought or sold PRCT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.27	-175,000	68,000	-%
Apr 22, 2024	RAYMOND JAMES & ASSOCIATES	new	-	491,828	491,828	-%
Apr 22, 2024	MetLife Investment Management, LLC	added	11.16	264,437	894,192	0.01%
Apr 19, 2024	Taylor Frigon Capital Management LLC	reduced	-32.1	-1,015,340	4,079,870	1.94%
Apr 18, 2024	Diversified Trust Co	added	25.43	215,154	664,303	0.02%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	22.97	3,052,860	9,835,910	0.01%
Apr 16, 2024	MCF Advisors LLC	added	42.31	2,217	5,486	-%
Apr 15, 2024	Legato Capital Management LLC	unchanged	-	315,187	2,074,110	0.25%
Apr 11, 2024	Ballentine Partners, LLC	sold off	-100	-5,574,030	-	-%
Apr 05, 2024	CWM, LLC	new	-	20,000	20,000	-%

Are Funds Buying or Selling PRCT?

Are funds buying PRCT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PRCT

No. of Funds

PRCT Alerts

1 major insider sales recently.

Unveiling PROCEPT BioRobotics Corporation's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	t. rowe price investment management, inc.	7.3%	3,695,027	SC 13G
Feb 13, 2024	vanguard group inc	8.29%	4,184,585	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	6.6%	3,357,638	SC 13G
Feb 14, 2023	viking global investors lp	0.0%	0	SC 13G/A
Feb 14, 2023	t. rowe price investment management, inc.	6.0%	2,697,885	SC 13G
Feb 09, 2023	vanguard group inc	7.23%	3,234,864	SC 13G
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Dec 07, 2022	cpmg inc	11.9%	5,328,867	SC 13D/A
Nov 16, 2022	cpmg inc	16.1%	7,192,469	SC 13D/A

Recent SEC filings of PROCEPT BioRobotics Corporation

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	DEF 14A	DEF 14A
Apr 22, 2024	DEFA14A	DEFA14A
Apr 19, 2024	4	Insider Trading
Apr 19, 2024	4/A	Insider Trading
Apr 19, 2024	4/A	Insider Trading
Apr 19, 2024	8-K	Current Report
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading

Peers (Alternatives to PROCEPT BioRobotics Corporation)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	185.5B	40.1B	-2.69%	-2.54%	32.41	4.63	-8.12%	-17.45%
BDX	67.5B	19.5B	-4.86%	-10.59%	53.77	3.46	4.02%	-22.04%
ALGN	23.6B	3.9B	-2.36%	-14.10%	52.95	6.1	3.42%	23.09%
BAX	20.8B	14.8B	-2.22%	-9.67%	7.83	1.4	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.49%	-14.47%	22.62	0.76	-2.44%	-22.68%
ATR	9.2B	3.5B	-1.02%	16.40%	32.49	2.65	4.97%	18.89%
BIO	8.1B	2.7B	-18.63%	-38.25%	-12.74	3.04	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.77%	-25.53%	-47.67	1.62	1.10%	85.84%
AXNX	3.4B	366.4M	-2.62%	10.65%	-560.04	9.28	33.86%	89.83%
PDCO	2.3B	6.6B	-4.73%	-4.84%	12.12	0.36	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.22%	-19.13%	-1.92	0.41	7.73%	-1066.14%
ANIK	384.6M	166.7M	1.30%	-3.37%	-4.65	2.31	6.67%	-456.34%
ANGO	235.1M	324.0M	12.50%	-31.24%	-1.22	0.73	-3.19%	-337.41%
APYX	52.0M	52.3M	5.60%	-56.15%	-2.78	0.99	17.61%	19.28%
AEMD	4.0M	3.7M	-11.70%	184.91%	-0.33	1.07	5.77%	8.23%

PROCEPT BioRobotics Corporation News

Latest updates

PROCEPT BioRobotics Corporation Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Revenue	24.2%	44.00	35.00	33.00	24.00	24.00	20.00	17.00	14.00	10.00	9.00	8.00	7.00	5.00	2.00
Cost Of Revenue	37.6%	22.00	16.00	15.00	12.00	13.00	10.00	8.00	7.00	6.00	4.00	5.00	4.00	-	2.00
Gross Profit	12.6%	21.00	19.00	18.00	12.00	11.00	10.00	8.00	8.00	5.00	4.00	4.00	4.00	-	-0.03
Operating Expenses	14.2%	51.00	44.00	44.00	41.00	36.00	32.00	26.00	23.00	21.00	17.00	17.00	15.00	-	11.00
S&GA Expenses	10.4%	36.00	33.00	32.00	30.00	26.00	25.00	20.00	18.00	16.00	12.00	12.00	10.00	-	7.00
R&D Expenses	25.0%	14.00	12.00	12.00	11.00	10.00	8.00	7.00	5.00	5.00	5.00	4.00	5.00	-	4.00
Interest Expenses	10.4%	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	-	1.00
Net Income	-11.7%	-27.50	-24.62	-25.28	-28.48	-28.17	-22.61	-19.18	-17.18	-18.35	-14.10	-14.58	-12.82	-15.28	-12.01
Net Income Margin	15.1%	-0.78*	-0.92*	-1.03*	-1.16*	-1.16*	-1.26*	-1.38*	-1.55*	-1.74*	-2.04*	-2.59*	-3.66*	-6.87*	-
Free Cashflow	-35.5%	-33.51	-24.72	-33.71	-41.27	-26.04	-21.36	-17.34	-18.29	-16.81	-12.86	-13.02	-15.24	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-3.9%	405	421	272	284	309	324	311	321	337	351	126
Current Assets	-4.9%	351	369	230	246	273	289	298	308	326	339	110
Cash Equivalents	-10.4%	257	287	150	181	222	249	270	284	304	320	101
Inventory	-5.8%	40.00	42.00	43.00	39.00	29.00	22.00	14.00	13.00	13.00	10.00	7.00
Net PPE	6.3%	29.00	27.00	16.00	12.00	9.00	5.00	4.00	5.00	5.00	6.00	8.00
Liabilities	1.8%	124	122	117	111	112	103	72.00	68.00	70.00	68.00	65.00
Current Liabilities	11.1%	46.00	41.00	36.00	33.00	35.00	27.00	19.00	15.00	16.00	14.00	15.00
Long Term Debt	0.1%	51.00	51.00	51.00	51.00	51.00	51.00	51.00	50.00	50.00	50.00	44.00
LT Debt, Non Current	0.1%	51.00	51.00	51.00	51.00	51.00	51.00	51.00	50.00	50.00	50.00	44.00
Shareholder's Equity	-6.2%	281	299	156	173	197	221	239	253	267	283	-182
Retained Earnings	-6.4%	-454	-427	-402	-377	-348	-320	-297	-278	-261	-243	-201
Additional Paid-In Capital	1.2%	735	726	558	550	546	541	537	532	529	527	19.00
Accumulated Depreciation	-	4.00	-	-	-	9.00	-	-	7.00	7.00	6.00	5.00
Shares Outstanding	0.6%	51.00	50.00	45.00	45.00	44.00	44.00	44.00	44.00	16.00	7.00	5.00
Float	-	-	-	1,400	-	-	-	1,000	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	-30.9%	-24,793	-18,943	-28,339	-35,928	-25,174	-19,851	-17,126	-18,231	-16,476	-12,751	-12,909	-15,198	-	-
Share Based Compensation	-6.5%	4,981	5,326	5,103	3,724	2,885	3,224	2,676	1,552	1,496	925	725	650	-	-
Cashflow From Investing	-50.8%	-8,715	-5,780	-5,372	-5,339	-866	-1,514	-218	-55.00	-332	-111	-110	-39.00	-	-
Cashflow From Financing	-98.2%	2,866	162,119	2,430	380	-1,318	777	2,862	1,291	644	174,122	86,125	1,225	-	-

PRCT Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue	$ 136,191	$ 75,014	$ 34,473
Cost of sales	65,142	37,929	18,608
Gross profit	71,049	37,085	15,865
Operating expenses:
Research and development	48,446	28,981	18,993
Selling, general and administrative	131,773	88,828	51,036
Total operating expenses	180,219	117,809	70,029
Loss from operations	(109,170)	(80,724)	(54,164)
Interest expense	(3,995)	(5,183)	(5,810)
Interest and other income, net	7,268	2,011	121
Loss on loan extinguishment	0	(3,258)	0
Net loss	$ (105,897)	$ (87,154)	$ (59,853)
Net loss per share, basic (in dollars per share)	$ (2.24)	$ (1.96)	$ (3.63)
Net loss per share, diluted (in dollars per share)	$ (2.24)	$ (1.96)	$ (3.63)
Weighted-average common shares used to
Basic (in shares)	47,255	44,400	16,480
Diluted (in shares)	47,255	44,400	16,480
Other comprehensive gain (loss):
Unrealized gain (loss) on cash equivalents	$ 90	$ 48	$ (40)
Comprehensive loss	$ (105,807)	$ (87,106)	$ (59,893)

PRCT Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 257,222	$ 221,859
Restricted cash, current	0	777
Accounts receivable, net	48,376	15,272
Inventory	39,756	28,543
Prepaid expenses and other current assets	5,213	6,175
Total current assets	350,567	272,626
Restricted cash, non-current	3,038	3,038
Property and equipment, net	28,748	8,656
Operating lease right-of-use assets, net	20,241	23,481
Intangible assets, net	1,204	1,477
Other assets	919	51
Total assets	404,717	309,329
Current liabilities:
Accounts payable	13,499	9,391
Accrued compensation	16,885	13,447
Deferred revenue	5,656	2,855
Operating leases, current	1,683	2,129
Loan facility derivative liability, current	1,886	0
Other current liabilities	6,318	7,468
Total current liabilities	45,927	35,290
Long-term debt	51,339	51,213
Operating leases, non-current	26,182	23,975
Loan facility derivative liability, non-current	0	1,779
Other non-current liabilities	517	0
Total liabilities	123,965	112,257
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000 and none shares authorized, none issued and outstanding as of December 31, 2022 and 2021, respectively	0	0
Common stock, $0.0001 par value: 300,000 and 40,000 shares authorized, 44,828 and 43,676 shares issued and outstanding as of December 31, 2022 and 2021, respectively	0	0
Additional paid-in capital	735,240	545,753
Accumulated other comprehensive gain (loss)	84	(6)
Accumulated deficit	(454,572)	(348,675)
Total stockholders’ equity	280,752	197,072
Total liabilities and stockholders’ equity	$ 404,717	$ 309,329

About PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.

CEO	Dr. Reza Zadno Ph.D.
WEBSITE	procept-biorobotics.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	428

PROCEPT BioRobotics Corporation Frequently Asked Questions

What is the ticker symbol for PROCEPT BioRobotics Corporation? What does PRCT stand for in stocks?

PRCT is the stock ticker symbol of PROCEPT BioRobotics Corporation. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PROCEPT BioRobotics Corporation (PRCT)?

As of Tue Apr 23 2024, market cap of PROCEPT BioRobotics Corporation is 2.74 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PRCT stock?

You can check PRCT's fair value in chart for subscribers.

What is the fair value of PRCT stock?

You can check PRCT's fair value in chart for subscribers. The fair value of PROCEPT BioRobotics Corporation is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of PROCEPT BioRobotics Corporation is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PRCT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is PROCEPT BioRobotics Corporation a good stock to buy?

The fair value guage provides a quick view whether PRCT is over valued or under valued. Whether PROCEPT BioRobotics Corporation is cheap or expensive depends on the assumptions which impact PROCEPT BioRobotics Corporation's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PRCT.

What is PROCEPT BioRobotics Corporation's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, PRCT's PE ratio (Price to Earnings) is -25.87 and Price to Sales (PS) ratio is 20.11. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PRCT PE ratio will change depending on the future growth rate expectations of investors.